Zacks Investment Research on MSN
Dexcom's G7 shows strong results in type 2 diabetes CONNECT study
DexCom, Inc. DXCM recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its ...
First-of-its-kind NIL program features 27 athletes with Type 1 diabetes across 13 sports, marking the program’s largest ...
The company continues the European rollout of DBLG2 and prepares new features and expanded indications to simplify diabetes ...
The twiist Automated Insulin Delivery System is now available for adults with insulin-treated type 2 diabetes.
Zacks Investment Research on MSN
Beta Bionics stock down despite iLet-Eversense 365 integration deal
Beta Bionics, Inc. BBNX recently announced a partnership with Senseonics SENS to expand compatibility between its automated insulin delivery (AID) platform and Senseonics’ continuous glucose ...
How big is the sensor patch market, and why is it growing so fast? The global sensor patch market is valued at USD 7.9 ...
For readers seeking more insight into food and activity habits, this Signos review examines glucose-monitoring features, ...
Tandem Mobi is powered by Control-IQ+ technology, the predictive algorithm that automates insulin delivery. The system uses a ...
Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and ...
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery system ...
ODYSS N1 uses AI and a camera to log meals automatically for $299, but its food recognition and calorie accuracy still need independent testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results